Advances in population pharmacokinetics-pharmacodynamics of caspofungin
- VernacularTitle:卡泊芬净的群体药代动力学-药效动力学研究进展
- Author:
Manna LI
1
,
2
;
Xiaoying LIN
1
,
2
;
Yinxuan HUANG
1
,
2
;
Hui XIE
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Guangzhou Medical University，Guangzhou 510120，China
2. School of Pharmacy，Guangzhou Medical University，Guangzhou 511436，China
- Publication Type:Journal Article
- Keywords:
caspofungin;
population pharmacokinetics-pharmacodynamics;
individualized medication;
children;
adult
- From:
China Pharmacy
2022;33(5):635-640
- CountryChina
- Language:Chinese
-
Abstract:
Caspofungin is the firs t echinocandin antifungal drug approved for serious fungal infections caused by Candida or Aspergillus. Currently ，caspofungin has been recommended as the first-line treatment for invasive Candida and the second-line treatment for invasive Aspergillus，for its safety and tolerability. However ，there are still probability of pharmacokinetic variability and the risk of low exposure in different populations. Herein the population pharmacokinetics-pharmacodynamics studies of caspofungin in children and adults were reviewed. The results indicate that the body surface area was the main factor affecting the distribution and clearance of caspofungin in pediatric patients. In adults ，the two-compartment model fits the caspofungin behavior best in vivo with the primary covariates of body weight and albumin level. The efficacy of caspofungin might be related to pharmacokinetics-pharmacodynamics parameters ，such as the ratio of area under blood concentration time curve to minimum inhibitory concentration （AUC/MIC），the ratio of peak concentration to minimum effective concentration （cmax/MEC）.
